Kristen Slaoui is Vice President and Head of Business Development for GlaxoSmithKline’s Global Pharmaceuticals Commercial Portfolio. She has spent nineteen years with GSK, first in R&D, where her work in pulmonary disease resulted in the discovery of the muscarinic receptor antagonist in the approved medicines Anoro™, Incruse™, and Trelegy™. Since joining GSK’s Business Development teams in 2006, she has executed more than $25 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009, participation in the $20+ billion three-part transaction with Novartis in 2015, and the recent $5.1 billion acquisition of TESARO, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals.  Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College.  She earned her Ph.D. in Physiology from The Johns Hopkins University Bloomberg School of Public Health and completed an NIH Post-Doctoral Fellowship in Pharmacology at the University of Washington in Seattle, WA.  After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins University Bloomberg School of Public Health in Baltimore, MD.